89bio, Inc. – NASDAQ:ETNB

89bio stock price today

$9
+1.12
+14.21%
Financial Health
0
1
2
3
4
5
6
7
8
9

89bio stock price monthly change

-10.25%
month

89bio stock price quarterly change

-10.25%
quarter

89bio stock price yearly change

-29.07%
year

89bio key metrics

Market Cap
918.31M
Enterprise value
463.56M
P/E
-4.79
EV/Sales
N/A
EV/EBITDA
-4.54
Price/Sales
N/A
Price/Book
3.28
PEG ratio
-0.13
EPS
-2.01
Revenue
N/A
EBITDA
-175.29M
Income
-165.03M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

89bio stock price history

89bio stock forecast

89bio financial statements

89bio, Inc. (NASDAQ:ETNB): Profit margin
Jun 2023 0 -38.39M
Sep 2023 0 -34.72M
Dec 2023 234K -40.23M -17194.44%
Mar 2024 0 -51.68M
89bio, Inc. (NASDAQ:ETNB): Analyst Estimates
Dec 2023 234K -40.23M -17194.44%
Mar 2024 0 -51.68M
Oct 2025 0 -68.05M
Dec 2025 0 -69.00M
  • Analysts Price target

  • Financials & Ratios estimates

89bio, Inc. (NASDAQ:ETNB): Debt to assets
Jun 2023 492511000 50.52M 10.26%
Sep 2023 460111000 49.90M 10.85%
Dec 2023 596269000 59.96M 10.06%
Mar 2024 577322000 66.78M 11.57%
89bio, Inc. (NASDAQ:ETNB): Cash Flow
Jun 2023 -34.44M -101.80M 30.76M
Sep 2023 -30.36M 38.32M -1.48M
Dec 2023 -34.29M -63.64M 162.17M
Mar 2024 -39.72M -79.89M 21.03M

89bio alternative data

89bio, Inc. (NASDAQ:ETNB): Employee count
Sep 2023 45
Oct 2023 45
Nov 2023 45
Dec 2023 45
Jan 2024 45
Feb 2024 45
Mar 2024 70
Apr 2024 70
May 2024 70
Jun 2024 70
Jul 2024 70

89bio other data

37.15% -61.08%
of ETNB is owned by hedge funds
12.93M -33.48M
shares is hold by hedge funds

89bio, Inc. (NASDAQ:ETNB): Insider trades (number of shares)
Period Buy Sel
Feb 2024 0 4477
Mar 2024 1350000 0
Apr 2024 0 52718
Oct 2024 0 27955
Nov 2024 3260000 0
Dec 2024 15000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
PALEKAR ROHAN director, officer.. Common Stock 5,000 $7.89 $39,450
Purchase
MCWHERTER CHARLES director Common Stock 10,000 $8 $80,000
Purchase
PALEKAR ROHAN director, officer.. Common Stock 10,000 $8.35 $83,500
Purchase
RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner:
Pre-Funded Warrants (Right to Buy) 3,250,000 $0 $3,250
Sale
LE-NGUYEN QUOC officer: See Rema.. Common Stock 27,955 $8.12 $226,995
Option
PALEKAR ROHAN director, officer.. Common Stock 25,000 $1.93 $48,250
Sale
PALEKAR ROHAN director, officer.. Common Stock 52,718 $10.91 $575,153
Option
PALEKAR ROHAN director, officer.. Stock Option (Right to Buy) 25,000 $1.93 $48,250
Purchase
RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner:
Common Stock 1,350,000 $15.35 $20,722,500
Sale
PALEKAR ROHAN director, officer.. Common Stock 4,477 $10.76 $48,173
Thursday, 19 December 2024
globenewswire.com
Monday, 16 December 2024
zacks.com
Friday, 29 November 2024
globenewswire.com
Friday, 15 November 2024
globenewswire.com
Tuesday, 12 November 2024
globenewswire.com
globenewswire.com
Tuesday, 5 November 2024
globenewswire.com
Tuesday, 15 October 2024
globenewswire.com
Friday, 11 October 2024
globenewswire.com
Monday, 30 September 2024
globenewswire.com
Thursday, 19 September 2024
globenewswire.com
Monday, 16 September 2024
globenewswire.com
Friday, 9 August 2024
globenewswire.com
Wednesday, 7 August 2024
seekingalpha.com
globenewswire.com
Monday, 5 August 2024
globenewswire.com
Friday, 12 July 2024
globenewswire.com
Friday, 14 June 2024
globenewswire.com
Thursday, 23 May 2024
seekingalpha.com
Wednesday, 22 May 2024
globenewswire.com
Tuesday, 14 May 2024
globenewswire.com
Friday, 10 May 2024
globenewswire.com
Thursday, 9 May 2024
globenewswire.com
Wednesday, 8 May 2024
globenewswire.com
Monday, 6 May 2024
Zacks Investment Research
Sunday, 10 March 2024
24/7 Wall Street
Tuesday, 5 March 2024
Zacks Investment Research
Zacks Investment Research
Wednesday, 6 December 2023
Seeking Alpha
Thursday, 26 October 2023
Seeking Alpha
  • What's the price of 89bio stock today?

    One share of 89bio stock can currently be purchased for approximately $9.

  • When is 89bio's next earnings date?

    Unfortunately, 89bio's (ETNB) next earnings date is currently unknown.

  • Does 89bio pay dividends?

    No, 89bio does not pay dividends.

  • How much money does 89bio make?

    89bio has a market capitalization of 918.31M.

  • What is 89bio's stock symbol?

    89bio, Inc. is traded on the NASDAQ under the ticker symbol "ETNB".

  • What is 89bio's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of 89bio?

    Shares of 89bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are 89bio's key executives?

    89bio's management team includes the following people:

    • Mr. Rohan Palekar Chief Executive Officer & Director(age: 59, pay: $869,650)
    • Dr. Harry Mansbach M.D. Chief Medical Officer(age: 60, pay: $650,000)
    • Mr. Quoc Le-Nguyen Chief Technical Operations Officer & Head of Quality(age: 57, pay: $555,380)
  • How many employees does 89bio have?

    As Jul 2024, 89bio employs 70 workers.

  • When 89bio went public?

    89bio, Inc. is publicly traded company for more then 5 years since IPO on 11 Nov 2019.

  • What is 89bio's official website?

    The official website for 89bio is 89bio.com.

  • Where are 89bio's headquarters?

    89bio is headquartered at 142 Sansome Street, San Francisco, CA.

  • How can i contact 89bio?

    89bio's mailing address is 142 Sansome Street, San Francisco, CA and company can be reached via phone at +41 54329270.

89bio company profile:

89bio, Inc.

89bio.com
Exchange:

NASDAQ

Full time employees:

70

Industry:

Biotechnology

Sector:

Healthcare

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

142 Sansome Street
San Francisco, CA 94104

CIK: 0001785173
ISIN: US2825591033
CUSIP: 282559103